Form 4: Director Jill DeSimone Increases Stake in Praxis
Statement of Changes in Beneficial Ownership
Director Jill DeSimone acquired 1,371 restricted stock units and 648 stock options in Praxis Precision Medicines, Inc.
Summary
- Director Jill DeSimone received an equity grant consisting of 1,371 restricted stock units (RSUs) and 648 stock options.
- The RSUs vest in a single installment on June 10, 2027, or the date of the 2027 annual meeting.
- The stock options have an exercise price of $240.66 and vest in twelve equal monthly installments starting July 10, 2026.
- Following these transactions, the director holds 2,337 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Retention of board leadership through standard vesting schedules.
Negatives
- Dilutive impact of new equity grants on existing shareholders.
Risks
- Market volatility affecting the value of equity-based compensation.
- Potential for future share price fluctuations impacting the exercise value of the granted options.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director compensation and equity ownership changes.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure long-term alignment with corporate performance and shareholder value.
Comparison to Industry Standards
- The use of RSU and option-based compensation is consistent with standard governance practices for mid-cap biotechnology firms.
- Vesting schedules tied to annual meetings are common for board members to ensure continuity.
Stakeholder Impact
- Shareholders may experience minor dilution from the issuance of new equity.
Next Steps
- Vesting of stock options beginning July 10, 2026.
- Vesting of restricted stock units on June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of grant for restricted stock units and stock options. |
| 07/10/2026 | First monthly vesting date for stock options. |
| 06/10/2027 | Vesting date for restricted stock units and final vesting date for options. |
| 06/10/2036 | Expiration date for stock options. |
Keywords
Praxis Precision Medicines, PRAX, Insider Trading, Form 4, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.